{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:22:44Z","timestamp":1794565364685,"version":"4.9.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ygyno.2026.05.018","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:43:11Z","timestamp":1779378191000},"page":"41-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Uptake of risk-reducing medical interventions among female BRCA1\/2 pathogenic variant carriers: A population-based study in British Columbia"],"prefix":"10.1016","volume":"210","author":[{"given":"Sabrina","family":"Lloyd-Ellis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paramdeep","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice S.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesa","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian E.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2026.05.018_bb0005","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0010","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of <i>BRCA1<\/i> and <i>BRCA2<\/i> penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0015","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.2015.62.3942","article-title":"Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1\/2 mutation carriers","volume":"34","author":"van den Broek","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0020","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkaa029","article-title":"Penetrance of breast and ovarian cancer in women who carry a BRCA1\/2 mutation and do not use risk-reducing salpingo-oophorectomy: an updated meta-analysis","volume":"4","author":"Chen","year":"2020","journal-title":"JNCI Cancer Spectr."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0025","first-page":"75","article-title":"American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography","volume":"57","author":"Saslow","year":"2007","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0030","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jnci\/93.21.1633","article-title":"Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers","volume":"93","author":"Hartmann","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1200\/JCO.2011.39.7638","article-title":"Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule","volume":"31","author":"Rosenthal","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0040","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2026.05.018_bb0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1470-2045(09)70026-9","article-title":"Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK collaborative trial of ovarian Cancer screening (UKCTOCS)","volume":"10","author":"Menon","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0050","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.2014.59.4945","article-title":"Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom collaborative trial of ovarian cancer screening","volume":"33","author":"Menon","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0055","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1245\/s10434-007-9449-x","article-title":"Prophylactic mastectomy in BRCA1\/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam family cancer clinic","volume":"14","author":"Heemskerk-Gerritsen","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0060","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJM200107193450301","article-title":"Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation","volume":"345","author":"Meijers-Heijboer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0065","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","article-title":"Risk-reducing salpingo-oophorectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study","volume":"26","author":"Kauff","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0070","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.6004\/jnccn.2017.0003","article-title":"NCCN guidelines insights: genetic\/familial high-risk assessment: breast and ovarian, version 2.2017","volume":"15","author":"Daly","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0080","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ygyno.2021.06.022","article-title":"Risk of cardiovascular disease among women carrying BRCA mutations after risk-reducing bilateral salpingo-oophorectomy: a population-based study","volume":"162","author":"do Valle","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0085","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2022.33.e51","article-title":"Bone health after RRBSO among BRCA1\/2 mutation carriers: a population-based study","volume":"33","author":"do Valle","year":"2022","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030711","article-title":"Long-term non-cancer risks in people with BRCA mutations following risk-reducing bilateral salpingo-oophorectomy and the role of hormone replacement therapy: a review","volume":"15","author":"Nitschke","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ygyno.2026.05.018_bb0095","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the North American Menopause Society","volume":"29","year":"2022","journal-title":"Menopause"},{"key":"10.1016\/j.ygyno.2026.05.018_bb0100","doi-asserted-by":"crossref","first-page":"viii28","DOI":"10.1093\/annonc\/mdt308","article-title":"Coming into focus: the nonovarian origins of ovarian cancer","volume":"24 Suppl 8","author":"Dubeau","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0105","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S1470-2045(11)70222-4","article-title":"The tubal hypothesis of ovarian cancer: caution needed","volume":"12","author":"Collins","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0110","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajog.2013.04.019","article-title":"The role of the fallopian tube in the origin of ovarian cancer","volume":"209","author":"Erickson","year":"2013","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0115","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00404-013-3041-3","article-title":"Revisiting the pathogenesis of ovarian cancer: the central role of the fallopian tube","volume":"289","author":"Dietl","year":"2014","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0120","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/ijgc-2023-004377","article-title":"Tubectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol","volume":"33","author":"Steenbeek","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.05.018_bb0125","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/carcin\/bgab107","article-title":"Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: a meta-analysis of observational studies","volume":"43","author":"Park","year":"2022","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ygyno.2026.05.018_bb0130","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","article-title":"Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and bowel project (NSABP-P1) breast cancer prevention trial","volume":"286","author":"King","year":"2001","journal-title":"Jama"},{"key":"10.1016\/j.ygyno.2026.05.018_bb0135","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00280-016-2959-0","article-title":"The selective estrogen receptor modulators in breast cancer prevention","volume":"77","author":"Li","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0140","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.3747\/co.26.4068","article-title":"Selected medical interventions in women with a deleterious BRCA mutation: a population-based study in British Columbia","volume":"26","author":"Hanley","year":"2019","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0145","series-title":"BC Cancer [Publisher] Data Extract","volume":"2025","author":"BC Cancer","year":"2024"},{"key":"10.1016\/j.ygyno.2026.05.018_bb0150","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.32725","article-title":"Economic evaluation of population-based BRCA1 and BRCA2 testing in Canada","volume":"7","author":"Sun","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ygyno.2026.05.018_bb0155","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.55324","article-title":"Cost-effectiveness of gene-specific prevention strategies for ovarian and breast cancer","volume":"7","author":"Wei","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ygyno.2026.05.018_bb0160","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","article-title":"Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomised controlled trial","volume":"387","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2026.05.018_bb0165","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-3-030-38474-6_6","article-title":"Hormone therapy in menopause","volume":"1242","author":"Paciuc","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0170","doi-asserted-by":"crossref","first-page":"A20","DOI":"10.1136\/ijgc-2024-IGCS.22","article-title":"PO009\/#913\u00a0implementation of a virtual provincial gynecologic cancer prevention and survivorship clinic (GCPSC) in Canada","volume":"34","author":"Dawson","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.05.018_bb0175","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000507503","article-title":"Nonsurgical prevention strategies in BRCA1 and BRCA2 mutation carriers","volume":"16","author":"Singer","year":"2021","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.ygyno.2026.05.018_bb0180","first-page":"15","article-title":"Oral contraceptive use in Canada","volume":"36","author":"Rotermann","year":"2025","journal-title":"Health Rep."},{"key":"10.1016\/j.ygyno.2026.05.018_bb0185","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/ijc.23340","article-title":"International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers","volume":"122","author":"Metcalfe","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2026.05.018_bb0190","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/GME.0000000000001421","article-title":"What information do healthcare professionals need to inform premenopausal women about risk-reducing salpingo-oophorectomy?","volume":"27","author":"Hickey","year":"2020","journal-title":"Menopause"},{"key":"10.1016\/j.ygyno.2026.05.018_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102825","article-title":"Barriers and interventions to improve the uptake of cancer risk management strategies in hereditary cancer syndromes: a narrative review","volume":"36","author":"Beshar","year":"2026","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826019955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826019955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:20:57Z","timestamp":1794561657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826019955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"alternative-id":["S0090825826019955"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.05.018","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uptake of risk-reducing medical interventions among female BRCA1\/2 pathogenic variant carriers: A population-based study in British Columbia","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}